Soft corticosteroids for local immunosuppression: Exploring the possibility for the use of loteprednol etabonate for islet transplantation

N. Bocca, A. Pileggi, Ruth Molano, S. Marzorati, W. Wu, N. Bodor, Camillo Ricordi, Peter Buchwald

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Transplantation of pancreatic islets into subcutaneous, neovascularized devices is one of the possibilities explored as part of our search for a cure of diabetes. We have recently reported that syngeneic transplantation in a subcutaneous prevascularized device can restore euglycemia and sustain long-term function in rats and that explanted grafts showed preserved islets and intense vascular networks. Because all of the transplanted tissue is localized within the device, if such a bioartificial pancreas approach is used, localized immunosuppression might provide sufficient protection against rejection to achieve long-term function, while also avoiding the serious systemic side effects and the susceptibility for opportunistic infections that are commonly associated with systemic immunosuppressive therapies as only much smaller and localized doses are needed. Soft steroids are obvious candidates because soft drugs are specifically designed to produce targeted local activity, but no systemic side effects due to prompt metabolic (preferably extrahepatic, e.g., hydrolytic) inactivation. However, local concentrations that are effective for immunosuppression, but non-toxic to insulin-producing β-cells have to be found, and nontrivial difficulties related to long-term local deliverability have to be addressed. Here, we report preliminary results obtained using in vitro studies with human islets used to establish a tentative therapeutic concentration range together with fully scaled three-dimensional finite element method (FEM)-based Comsol multiphysics computational models that were used to explore various possibilities to achieve and maintain these concentration levels within the device.

Original languageEnglish
Pages (from-to)226-232
Number of pages7
JournalPharmazie
Volume63
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Islets of Langerhans Transplantation
Immunosuppression
Adrenal Cortex Hormones
Equipment and Supplies
Immunosuppressive Agents
Medical problems
Grafts
Rats
Steroids
Isogeneic Transplantation
Insulin
Tissue
Finite element method
Opportunistic Infections
Pharmaceutical Preparations
Blood Vessels
Pancreas
Transplants
Loteprednol Etabonate
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Soft corticosteroids for local immunosuppression : Exploring the possibility for the use of loteprednol etabonate for islet transplantation. / Bocca, N.; Pileggi, A.; Molano, Ruth; Marzorati, S.; Wu, W.; Bodor, N.; Ricordi, Camillo; Buchwald, Peter.

In: Pharmazie, Vol. 63, No. 3, 01.03.2008, p. 226-232.

Research output: Contribution to journalArticle

@article{ba7fc8f7f48c4be0a02a172dec75fbd1,
title = "Soft corticosteroids for local immunosuppression: Exploring the possibility for the use of loteprednol etabonate for islet transplantation",
abstract = "Transplantation of pancreatic islets into subcutaneous, neovascularized devices is one of the possibilities explored as part of our search for a cure of diabetes. We have recently reported that syngeneic transplantation in a subcutaneous prevascularized device can restore euglycemia and sustain long-term function in rats and that explanted grafts showed preserved islets and intense vascular networks. Because all of the transplanted tissue is localized within the device, if such a bioartificial pancreas approach is used, localized immunosuppression might provide sufficient protection against rejection to achieve long-term function, while also avoiding the serious systemic side effects and the susceptibility for opportunistic infections that are commonly associated with systemic immunosuppressive therapies as only much smaller and localized doses are needed. Soft steroids are obvious candidates because soft drugs are specifically designed to produce targeted local activity, but no systemic side effects due to prompt metabolic (preferably extrahepatic, e.g., hydrolytic) inactivation. However, local concentrations that are effective for immunosuppression, but non-toxic to insulin-producing β-cells have to be found, and nontrivial difficulties related to long-term local deliverability have to be addressed. Here, we report preliminary results obtained using in vitro studies with human islets used to establish a tentative therapeutic concentration range together with fully scaled three-dimensional finite element method (FEM)-based Comsol multiphysics computational models that were used to explore various possibilities to achieve and maintain these concentration levels within the device.",
author = "N. Bocca and A. Pileggi and Ruth Molano and S. Marzorati and W. Wu and N. Bodor and Camillo Ricordi and Peter Buchwald",
year = "2008",
month = "3",
day = "1",
doi = "10.1691/ph.2008.7774",
language = "English",
volume = "63",
pages = "226--232",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "3",

}

TY - JOUR

T1 - Soft corticosteroids for local immunosuppression

T2 - Exploring the possibility for the use of loteprednol etabonate for islet transplantation

AU - Bocca, N.

AU - Pileggi, A.

AU - Molano, Ruth

AU - Marzorati, S.

AU - Wu, W.

AU - Bodor, N.

AU - Ricordi, Camillo

AU - Buchwald, Peter

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Transplantation of pancreatic islets into subcutaneous, neovascularized devices is one of the possibilities explored as part of our search for a cure of diabetes. We have recently reported that syngeneic transplantation in a subcutaneous prevascularized device can restore euglycemia and sustain long-term function in rats and that explanted grafts showed preserved islets and intense vascular networks. Because all of the transplanted tissue is localized within the device, if such a bioartificial pancreas approach is used, localized immunosuppression might provide sufficient protection against rejection to achieve long-term function, while also avoiding the serious systemic side effects and the susceptibility for opportunistic infections that are commonly associated with systemic immunosuppressive therapies as only much smaller and localized doses are needed. Soft steroids are obvious candidates because soft drugs are specifically designed to produce targeted local activity, but no systemic side effects due to prompt metabolic (preferably extrahepatic, e.g., hydrolytic) inactivation. However, local concentrations that are effective for immunosuppression, but non-toxic to insulin-producing β-cells have to be found, and nontrivial difficulties related to long-term local deliverability have to be addressed. Here, we report preliminary results obtained using in vitro studies with human islets used to establish a tentative therapeutic concentration range together with fully scaled three-dimensional finite element method (FEM)-based Comsol multiphysics computational models that were used to explore various possibilities to achieve and maintain these concentration levels within the device.

AB - Transplantation of pancreatic islets into subcutaneous, neovascularized devices is one of the possibilities explored as part of our search for a cure of diabetes. We have recently reported that syngeneic transplantation in a subcutaneous prevascularized device can restore euglycemia and sustain long-term function in rats and that explanted grafts showed preserved islets and intense vascular networks. Because all of the transplanted tissue is localized within the device, if such a bioartificial pancreas approach is used, localized immunosuppression might provide sufficient protection against rejection to achieve long-term function, while also avoiding the serious systemic side effects and the susceptibility for opportunistic infections that are commonly associated with systemic immunosuppressive therapies as only much smaller and localized doses are needed. Soft steroids are obvious candidates because soft drugs are specifically designed to produce targeted local activity, but no systemic side effects due to prompt metabolic (preferably extrahepatic, e.g., hydrolytic) inactivation. However, local concentrations that are effective for immunosuppression, but non-toxic to insulin-producing β-cells have to be found, and nontrivial difficulties related to long-term local deliverability have to be addressed. Here, we report preliminary results obtained using in vitro studies with human islets used to establish a tentative therapeutic concentration range together with fully scaled three-dimensional finite element method (FEM)-based Comsol multiphysics computational models that were used to explore various possibilities to achieve and maintain these concentration levels within the device.

UR - http://www.scopus.com/inward/record.url?scp=41349115062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349115062&partnerID=8YFLogxK

U2 - 10.1691/ph.2008.7774

DO - 10.1691/ph.2008.7774

M3 - Article

C2 - 18444512

AN - SCOPUS:41349115062

VL - 63

SP - 226

EP - 232

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 3

ER -